Ameriprise
IMDX

Ameriprise’s Insight Molecular Diagnostics IMDX Stock Holding History

Ameriprise’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,235
Closed -$10.3K – 3943
2023
Q2 		$10.3K Buy
2,235
+115
+5% +$579 ﹤0.01% 3892
2023
Q1 		$15K Sell
2,120
-25
-1% -$186 ﹤0.01% 3904
2022
Q4 		$14K Sell
2,145
-150
-7% -$1.65K ﹤0.01% 3916
2022
Q3 		$34K Buy
2,295
+1,605
+233% +$27.8K ﹤0.01% 3908
2022
Q2 		$12K Sell
690
-7
-1% -$159 ﹤0.01% 3862
2022
Q1 		$21K Buy
697
+13
+2% +$416 ﹤0.01% 3903
2021
Q4 		$30K Sell
684
-5
-0.7% -$288 ﹤0.01% 3919
2021
Q3 		$49K Buy
+689
New +$63.3K ﹤0.01% 3817
2021
Q1 		– Sell
-3,424
Closed -$164K – 3883
2020
Q4 		$164K Sell
3,424
-25
-0.7% -$917 ﹤0.01% 3645
2020
Q3 		$96K Buy
3,449
+20
+0.6% +$573 ﹤0.01% 3644
2020
Q2 		$131K Sell
3,429
-75
-2% -$3.87K ﹤0.01% 3557
2020
Q1 		$172K Buy
3,504
+78
+2% +$3.82K ﹤0.01% 3466
2019
Q4 		$154K Sell
3,426
-15
-0.4% -$541 ﹤0.01% 3612
2019
Q3 		$145K Buy
3,441
+76
+2% +$2.99K ﹤0.01% 3607
2019
Q2 		$168K Hold
3,365
– – ﹤0.01% 3607
2019
Q1 		$266K Buy
+3,365
New +$217K ﹤0.01% 3482

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's IMDX Position: Q3 2023 in Review

Ameriprise sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 2,235 shares — an estimated $10.3K sold.

Ameriprise first reported a position in IMDX in Q1 2019 and held it in 16 quarters. The position peaked at $266K in Q1 2019. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Ameriprise reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Ameriprise sold 2,235 Insight Molecular Diagnostics shares in Q3 2023, an estimated $10.3K.
  • Ameriprise first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 16 quarters.
  • Ameriprise's Insight Molecular Diagnostics position peaked at $266K in Q1 2019.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.